Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-01-31
2006-01-31
Ketter, James (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S325000, C536S023100
Reexamination Certificate
active
06992070
ABSTRACT:
The present provides methods and compositions that enable effective delivery of nucleic acids to desired cells, including to a solid organ such as a mammalian heart. The methods and compositions enable effective gene transfer and subsequent expression to a majority of cells throughout a solid organ such as the heart. Methods and compositions of the invention preferably provide enhanced vascular permeability that enables increased gene transfer to targeted cells, but without significant degradation or injury to endothelial cell layers.
REFERENCES:
patent: 5516651 (1996-05-01), Goldring et al.
patent: 6100270 (2000-08-01), Campbell
patent: 6214620 (2001-04-01), Johns et al.
patent: 2002/0082240 (2002-06-01), Linden et al.
patent: 2002/0094326 (2002-07-01), Donahue et al.
patent: WO 96/16657 (1996-06-01), None
patent: WO 99/19792 (1999-04-01), None
patent: WO 99/31982 (1999-07-01), None
Carson CC Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients, Curr. Urol. Rep. Dec.; 2003 4(6) pp488-496.
Crocker I.C. therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases Drugs Today. Jul.; 1999 35(7): pp519-3 and DeKorte C.J. Current and emerging therapies for the management of chronic inflammation in asthma Am J. Health Syst. Pharm.
Netherton S.J. et al. Altered PDE-e mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells:implications for diabitets associated cardiovasular diease. Diabetes. Apr.; 2002 51(4):1194 200.
Anderson Human Gene Therapy Nature vol. 392, supp 1998 pp 25-30.
Verma et al. Gene therapy—promises, problems and prospects Nature vol. 389 1997 pp239-242.
Palu et al. In pursuit of new deveopments for gene therapy of human diseases J. of Biotech. vol. 68 1999 pp1-12.
DeKorte C.J. Current and emerging therapies for the management of chronic inflammation in asthma Am J. Health Syst. Pharm Oct. 1. 2003; (60)19: pp1949-59.
Lamping, K, et al., “Agonist-specific impairment of coronary vascular function in genetically altered, hyperlipidemic mice,”Am. J. of Phys., (Apr. 1999), pp. R1023-R1029, vol. 276, No. 4.
Kuwahara, A. et al., “5-HT activates nitric oxide-generating neurons to stimulate chloride secretion in guinea pig distal colon,”Am. J. Phys., (Oct. 1998), pp. G829-G834, vol. 275, No. 4.
Frieden, M. et al., “Effect of 5-hydroxytriptamine on the membrane potential of endothial and smooth muscle cells in the pig coronary artery,”British Journal of Pharmacology, (1995), pp. 95-100, vol. 115, No. 1.
Reiser, G., “Nitric oxide formation caused by calcium release from internal stores in neuronal cell line in enhanced by cyclic amp,”European Journal of Pharmacology Molecular Pharmacology Section, (1992), pp. 89-93, vol. 9, No. 1.
Katz, S. et al., “Acute type 5 phosphodiesterase inhibition with slidenafil enhances flow-mediated vasodilation in patients with chronic heart failure,”Journal of the American College of Cardiology, (Sep. 2000), pp. 845-851, vol. 36, No. 3.
Lai, N.C. et al., “Sodium nitroprusside facilitates intracoronary gene transfer in pigs,”Faseb Journal, (Mar. 2001), p. A100. vol. 15, No. 4.
Bilbao, R. et al., “A blood-tumor barrier limits gene transfer to the experimental liver cancer: The effect of vasoactive compounds,”Gene Therapy, (Nov. 2000), pp. 1824-1832, vol. 7, No. 21.
Corbin, J.D., et al., “Pharmacology of Phosphodiesterase-5 Inhibitors,”IJCP, (Jul./Aug. 2002), pp. 453-459, vol. 56, No. 6.
Eardly, I. et al., “Tadalafil (Cialis) for Men with Erectile Dysfunction,”IJCP, (May 2002), pp. 300-304, vol. 56, No. 4.
Donahue, J.K. et al., “Ultrarapid, highly efficient viral gene transfer to the heart,”PNAS, (Apr. 1997), pp. 4664-4668, vol. 94.
Donahue, J.K. et al., “Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin,”Gene Therapy, (1998), pp. 630-634, vol. 5.
Hetman, J.M. et al., “Cloning and characterization of PDE7B a cAMP-specific phosphodiesterase,”PNAS, (Jan. 2004), pp. 472-476, vol. 97, No. 1.
Nagata, K. et al., “Phosphodiesterase Inhibitor-mediated Potentiationo f Adenovirus Delivery to Myocardium,”J. Mol. Cell. Cardiol., (2001), pp. 575-580, vol. 33.
Sung, B. et al., “Structure of the catalytic domain of human phosphodiesterase 5 wit bound drug molecules,”Nature, (Sep. 2003), pp. 98-102, vol. 425.
Lenhart, S.E. et al., “Preservation of myocardial function after adenoviral gene transfer in isolated myocardium,”Am. J. Physiol. Hart Circ. Physiol., (2000), pp. H986-H991, vol. 279.
Rotella, D., “Phosphodiesterase 5 inhibitors: Current Status and Potential Applications,”Nature, (Sep. 2002), pp. 674-682, vol. 1.
Soderling, S.H. et al., “Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodieterase,”PNAS, (Jul. 1998), pp. 8991-8996, vol. 95.
Barr, E. et al., “Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus,”Gene Therapy, (Jan. 1994), pp. 51-58, vol. 1, No. 1 (Abstract Only).
Ding, Z. et al., “A minimally invasive approach for efficient gene delivery to rodent hearts,”Gene Therapy, (Feb. 2004), pp. 260-265, vol. 11, No. 3 (Abstract Only).
Inoue H. et al., “T-1032, a novel specific phosphodiesterase type 5 Inhibitor increases venous compliance in anesthetized rats,”Eur. J. Pharmacol., (Jun. 2001), pp. 109-114, vol. 422, No. 1-3 (Abstract Only).
Takagi, M. et al., “Pharmacologicla profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit copus cavernosum,”Eur. J. Pharmacol., (Jun. 2001), pp. 161-168, vol. 411, No. 1-2 (Abstract Only).
Donahue J. Kevin
Lawrence John H.
Marban Eduardo
Nagata Koichi
Banner & Witcoff , Ltd.
Katcheves Konstantina M.
Ketter James
The Johns Hopkins University
LandOfFree
Methods and compositions for nucleic acid delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for nucleic acid delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for nucleic acid delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3586341